Table 1.
Patient baseline characteristics
| Parameters | Median | (IQR) |
|---|---|---|
| Age | 72 | (44.7-87.5) |
| Gleason score | 8 | (7.8-8.4) |
| PSA (ng/ml) | 294 | (2.74-7190) |
| ECOG PS | n | % |
| 0-1 | 85 | 77.3 |
| 2 | 21 | 19.1 |
| unknown | 4 | 3.6 |
| Alkaline phosphatase (U/l) | 173 | (38-1033) |
| LDH (U/l) | 326 | (160-7802) |
| Site of metastases | n | % |
| Bone | 102 | 93.5 |
| Lymph node | 87 | 79.8 |
| Liver | 34 | 31.2 |
| Lung | 24 | 22.0 |
| other | 2 | 1.8 |
| Previous therapy of mCRPC | 109 | 100% |
| Docetaxel | 93 | 85.3 |
| Cabazitaxel | 28 | 25.7 |
| Abiraterone | 91 | 83.4 |
| Enzalutamide | 93 | 85.3 |
| Both (Abiraterone & Enzalutamide) | 86 | 78.9 |
| 223Radium | 22 | 20.1 |
| External beam radiation to bone | 47 | 43.1 |
PSA = Prostate-specific antigen; ECOG PS = Eastern Co-operative Oncology Group Performance Status; LDH = Lactate Dehydrogenase; mCRPC = metastatic Castration-Resistant Prostate Cancer.